Gal-3 has been considered in neurodevelopment, neuroinflammation, and neurodegeneration, also regarding its interplay with neurotransmitters (Borovcanin et al., 2021a), as well as its possible modulation by antipsychotic treatment and consequent obesity and cognitive changes in schizophrenia (Borovcanin et al., 2021b). The gene discussed is LGALS3; the disease is obesity disorder.